Health
Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average
The European Commission has granted final approval of a higher 7.2 mg maintenance dose of Wegovy® (semaglutide) for adults who may need extra help losing weight. It is now approved in all 27 countries in the European UnionIn a study with 1,407 people, lasting about 1½ years, those on the higher dose lost, on average, about one‑fifth of their body weight.Wegovy is now approved in the EU as a once‑weekly injection in six doses to help with weight management, used together with healthy eating and i
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Sq36MpNFOiz.w6RiXrpsqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The European Commission has granted final approval of a higher 7.2 mg maintenance dose of Wegovy® (semaglutide) for adults who may need extra help losing weight. It is now approved in all 27 countries in the European Union","length":222,"tagName":"p"}]},{"val":[{"type":"text","content":"In a study with 1,407 people, lasting about 1½ years, those on the higher dose lost, on average, about one‑fifth of their body weight.","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"Wegovy is now approved in the EU as a once‑weekly injection in six doses to help with weight management, used together with healthy eating and increased physical activity.","length":171,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":527,"olType":false},{"type":"text","content":"Bagsværd, Denmark, 17 February 2026 – The European Commission has approved a new 7.2 mg once‑weekly maintenance dose of Wegovy® (semaglutide injection) for adults living with obesity. This gives doctors another option to help adults who need more weight loss after being on the 2.4 mg dose. The approval is based on a positive opinion from the European Medicines Agency’s scientific committee (CHMP) on 12 December 2025.","length":420,"tagName":"p"},{"type":"text","content":"The approval means that doctors in the EU may now prescribe the 7.2 mg dosage as three 2.4 mg injections, to be taken in one sitting, still once a week. Novo Nordisk has applied for approval of a 7.2 mg single-dose pen in the EU, and if approved, it could be available this year. This means that in the European Union (EU), adults with obesity may now step directly from Wegovy® 2.4 mg (for at least four weeks) up to 7.2 mg if they need greater weight loss while preserving muscle function.","length":491,"tagName":"p"},{"type":"text","content":"Wegovy® 7...